BMS and J&J first linked together in 2018 to develop factor X1a inhibitors as anti-coagulants. The three Phase III Librexia ...

Bayer has let go of about 13,500 employees, including around 5,000 managers, since implementing a new operating model in ...

Merck has made several big-ticket deals this year, led by its $10 billion buyout of Verona Pharma in July, giving the pharma ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration ...

Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, actively working to remove obstacles to innovation.

Speaking at a conference this morning, Pfizer CEO Albert Bourla suggested that Metsera’s therapies could begin hitting the ...